1. Home
  2. LEGN vs CUBE Comparison

LEGN vs CUBE Comparison

Compare LEGN & CUBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CUBE
  • Stock Information
  • Founded
  • LEGN 2014
  • CUBE 2004
  • Country
  • LEGN United States
  • CUBE United States
  • Employees
  • LEGN N/A
  • CUBE N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CUBE Real Estate Investment Trusts
  • Sector
  • LEGN Health Care
  • CUBE Real Estate
  • Exchange
  • LEGN Nasdaq
  • CUBE Nasdaq
  • Market Cap
  • LEGN 5.4B
  • CUBE 9.9B
  • IPO Year
  • LEGN 2020
  • CUBE 2004
  • Fundamental
  • Price
  • LEGN $35.64
  • CUBE $43.34
  • Analyst Decision
  • LEGN Strong Buy
  • CUBE Buy
  • Analyst Count
  • LEGN 13
  • CUBE 14
  • Target Price
  • LEGN $75.17
  • CUBE $48.57
  • AVG Volume (30 Days)
  • LEGN 2.0M
  • CUBE 1.7M
  • Earning Date
  • LEGN 08-08-2025
  • CUBE 07-31-2025
  • Dividend Yield
  • LEGN N/A
  • CUBE 4.80%
  • EPS Growth
  • LEGN N/A
  • CUBE N/A
  • EPS
  • LEGN N/A
  • CUBE 1.69
  • Revenue
  • LEGN $728,303,000.00
  • CUBE $1,079,894,000.00
  • Revenue This Year
  • LEGN $65.49
  • CUBE $2.55
  • Revenue Next Year
  • LEGN $53.76
  • CUBE $3.65
  • P/E Ratio
  • LEGN N/A
  • CUBE $25.65
  • Revenue Growth
  • LEGN 112.46
  • CUBE 1.89
  • 52 Week Low
  • LEGN $27.34
  • CUBE $34.24
  • 52 Week High
  • LEGN $60.87
  • CUBE $55.14
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 57.79
  • CUBE 58.11
  • Support Level
  • LEGN $32.42
  • CUBE $41.50
  • Resistance Level
  • LEGN $36.91
  • CUBE $43.25
  • Average True Range (ATR)
  • LEGN 1.42
  • CUBE 0.81
  • MACD
  • LEGN 0.02
  • CUBE -0.02
  • Stochastic Oscillator
  • LEGN 67.58
  • CUBE 86.38

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CUBE CubeSmart

CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.

Share on Social Networks: